Skip main navigation

Main contents starts here

History: 1985 - 1999

Takeda Medicines are Now Used Worldwide


TAP Pharmaceuticals Inc. established, begins sales of Lupron®

In 1985, Takeda formed TAP Pharmaceuticals Inc. in the U.S. in a 50:50 joint venture with Abbott Laboratories. TAP began marketing the prostate cancer treatment Lupron® in the same year.


Tsukuba Research Laboratories established
The Tsukuba Research Center

The Tsukuba Research Center

Tsukuba Research Laboratories became Takeda's second research base, coupled with the one in Osaka. These laboratories conduct basic research using cutting-edge technologies.


Lupron Depot® launched


Effective for one full month with a single dosing, this was the successor to Lupron®. It is now sold in around 80 countries worldwide, and is considered a gold standard therapy for prostate cancer. Also on the market now are 4 Month Depot (one dosing every 4 months) in the U.S.


Lansoprazole (proton pump inhibitor and anti-peptic ulcer agent) launched in Europe


Lansoprazole is now sold in around 90 countries.

The success of Lupron Depot® and Prevacid® helped Takeda solidify its position as a global pharmaceutical manufacturer. These two drugs each now have worldwide sales exceeding $1 billion and have given us a firm business foundation in the U.S. and Europe.
In recent years, we further solidified our overseas bases to prepare for our new blockbuster drugs and aimed at greater business expansion.


Candesartan Cilexetil (angiotensin II receptor antagonist and anti-hypertensive agent) launched in Europe
Candesartan Cilexetil

Candesartan Cilexetil

Candesartan is rebolutionizing hypertension treatment. In around 60 countries worldwide, it enjoys a trusted reputation in the medical profession.

Improvement of the business infrastructure in overseas


Takeda UK Limited, a wholly owned pharmaceutical marketing subsidiary, established in the U.K.

Takeda Ireland Limited, a pharmaceutical manufacturing plant, established
Takeda Ireland Limited

Takeda Ireland Limited

Takeda Ireland Ltd has been working to meet the sharp increase in demand in the United States and Europe.

Takeda America Research & Development Center Inc. established

Takeda America Holdings, Inc., a holding company for our U.S. pharmaceutical business, established


Majority share acquired in Takeda Italia Farmaceutici S.p.A., a pharmaceutical marketing company in Italy

Laboratoires Takeda, a pharmaceutical marketing joint venture in France, becomes a wholly owned subsidiary of Takeda

Takeda Pharmaceuticals America, Inc. (now Takeda Pharmaceuticals North America, Inc.), a wholly owned pharmaceutical marketing company, established in the U.S.

Takeda Pharmaceuticals America, Inc. began marketing the insulin sensitizer Actos® in the next year.

Takeda Pharma AG, a pharmaceutical marketing company, established in Switzerland

Takeda Europe Research & Development Centre Ltd., (now Takeda Global Research & Development Centre (Europe), Ltd.) a pharmaceutical development company, established in the U.K.


Actos® (Pioglitazone Hydrochloride) launched in the U.S. and Japan
Pioglitazone Hydrochloride

Pioglitazone Hydrochloride

Actos® improves insulin resistance and reduce blood sugar levels. It is marketed in around 80 countries worldwide. It has become Takeda's top-selling product.

Skip side navigation


Skip sub navigation

Page Top